Purchase this article with an account.
Christopher Welsh, Solin Saleh, Chloe Gottlieb; Treatment of noninfectious intermediate uveitis with dexamethasone (Ozurdex) intravitreal implant.. Invest. Ophthalmol. Vis. Sci. 2018;59(9):416.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the efficacy and safety of the Ozurdex (Allergan, Inc, Irvine, California) sustained-release intravitreal dexamethasone implant for the treatment of noninfectious intermediate uveitis over approximately 6 months in therapy naïve patients, and those on systemic immunosuppressive therapy.
Retrospective review of demographic information, clinical data and optical coherence tomography (OCT) scans from patients with non-infectious intermediate uveitis treated with Ozurdex at the University of Ottawa Eye Institute between September 1, 2010 and December 1, 2016. Demographics and clinical information, including pre- and post-treatment best-corrected visual acuity (BCVA), intraocular pressure (IOP), anterior chamber and vitreous inflammation following SUN grading, and central retinal thickness (CRT) and presence of cystoid macular edema (CME) on OCT were analyzed.
The charts of 22 patients and 33 eyes with at least 6 months of follow up after Ozurdex implant were included. Mean age was 45.09 years, and 15 patients were female. Nine out of 22 patients (40.9%) were on systemic immunosuppressive therapy. Mean pre- and 6-month post-treatment BCVA was ~20/35 and ~20/25 respectively (p=0.038). Mean pre- and post-treatment CRT was 383.3 microns and 294.8 microns, respectively (p=0.0001). At the last follow-up appointment, there was resolution of CME in 83.3% of patients. Complete resolution of all intraocular inflammation was seen in 63.6% of our sample. IOP was not significantly raised post-treatment. Adverse events after Ozurdex injection included blurred vision in 57.6%, floaters in 54.5%, and photophobia in 15.2%. These had resolved at the last follow-up appointment in greater than 80% of the patients. BCVA improvement and CRT change was not significantly different between treatment naïve and systemically treated patients.
Ozurdex was effective in treating intermediate uveitis with statistically significant improvements in BCVA and CRT at 6 months, and most patients having complete resolution of their intraocular inflammation. Adverse effects were difficult to attribute to either the treatment or disease process, but most resolved by the last follow-up appointment. Ozurdex appears to be a safe and effective treatment for noninfectious intermediate uveitis.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only